Videos

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss their institution’s approaches to treatment decision making for patients with resectable non-small cell lung cancer.

Medical professionals discuss perspectives on CheckMate-77T trial results and potential impacts on clinical practice.

Dr. Hammers shares his experience with high-grade AEs in IO-TKI treated patients and how toxicities are mitigated/managed.

Dr. Hammers explains factors involved in decision-making between immunotherapy-based treatment options.

Valentina Ardila, MD, discusses findings from a study investigating the role of obesity in patients undergoing stem cell transplants.

Raajit K. Rampal, MD, PhD, discusses the MANIFEST-2 trial, a phase 3 study comparing ruxolitinib vs pelabresib and ruxolitinib combined with placebo for the treatment of myelofibrosis.

Experts review the NEOTORCH study of 400 patients showing favorable outcomes with a hazard ratio for event-free survival of 0.4.

Tina Cascone, MD, PhD, analyzes results from the AEGEAN trial evaluating perioperative immunotherapy in stage II-IIIB non-small cell lung cancer.

Alice Bertaina, MD, discusses combining of T-allo10, a donor-derived cell product, with haploidentical stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.

Overview of side effects and management when combining these agents.

Highlight key findings in the KRYSTAL-7 trial.

Patrick Forde, MBBCh, discusses CheckMate-816 study results, including the high pathological complete response rates within 6 weeks of immunotherapy reported in the trial's third arm.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss personalized treatment approaches for non-small cell lung cancer tailored to individual patient needs and goals.

Daniel Cancilla, MD, discusses a study performed at the Cleveland Clinic where a new protocol for plerixafor usage for stem cell transplantation was implemented with the goal of cost savings.

Peterson discusses the investigation of ruxolitinib in the second line for patients with acute graft-vs-host disease following allogeneic hematopoietic stem cell transplant.

Panelists examine multidisciplinary teams and coordination of care for patients with non-small cell lung cancer, including when to involve surgeons, oncologists, and radiation oncologists.

Medical professionals discuss the role of neoadjuvant/perioperative immunotherapy in subgroups of patients with NSCLC with actionable genomic aberrations, including a brief look at the ALINA and ADUARA trials.

Patrick Forde, MBBCh, and Tina Cascone, MD, PhD, discuss the role of molecular profiling to guide precision treatment decisions in non-small cell lung cancer, including the impact of PD-L1 status on neoadjuvant and perioperative approaches.

Hedyeh Ebrahimi, MD, MPH, discusses a study that found adding the live bacterial product CBM588 to standard immunotherapy potentially impacted patients' responses in renal cell carcinoma.

Abdullah M. Khan, MBBS, discusses the recent updates to data on the use of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Betty K. Hamilton, MD, discusses findings from a study comparing gilteritinib vs placebo post-allogeneic hematopoietic cell transplantation for the treatment of patients with FLT3-ITD-positive acute myeloid leukemia.

Michael Scordo, MD, discusses the implications of a new approach to dosing antithymocyte globulin in patients undergoing an allogeneic hematopoietic stem cell transplant.

Following a comprehensive review of CAPItello-291, Rohit Gosain, MD, and Rahul Gosain, MD, provide closing thoughts on key takeaways.

Focusing on the safety profile, the Oncology Brothers and Hope Rugo, MD, review safety data from CAPItello-291 and discuss adverse event management practices for patients with breast cancer.

Hope Rugo, MD, reviews key data from CAPItello-291 on capivasertib in patients with HR+ breast cancer, highlighting progression-free survival and overall survival.

Medical oncologists provide insights on biomarker testing and the prevalence of AKT1, PIK3CA, and PTEN mutations in breast cancer.

Hope Rugo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the rationale and study design for CAPItello-291 in HR+ advanced breast cancer.

Adam Binder, MD, discusses what he found to be notable from the results of the phase 3 BOSTON trial that looked at the efficacy of selinexor, bortezomib, and dexamethasone triplet therapy for patients with relapsed/refractory multiple myeloma.

Matthew Matasar, MD, highlights the use of mosunetuzumab-axgb for the treatment of patients with follicular lymphoma.

Ibrahim N. Muhsen, MD, discusses the findings and key takeaways from his presentation given at the 2024 Tandem Meeting.